TWST
Bearish signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Twist Bioscience Corporation
- Nom
- Twist Bioscience Corporation
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $9.1B
- Employés
- 979
- PDG
- Emily Marine Leproust
- Site web
- https://www.twistbioscience.com
- Marché
- GNNSFLZAGYRGENSDMHFWUXIFWXIBF
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 416 677 titres (~65 157 503,08 $ US)
- Insiders
- Leproust Emily M.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$46,620,914
Avg sell (VWAP, 90d window) $143.97 vs last close $145.25 (+0.9%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$29,431,073 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-05
- Liquidity
- Liquid $454,305,048/day · 20d vol
- Last synced
-
2026-10-27 06:51:29
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-09 | Laponis Adam | Sell · S | 2,462 | $156.30 | $384,823 | Form 4 |
| 2026-10-05 | Leproust Emily M. | Sell · S · 10b5-1 | 45 | $207.46 | $9,336 | Form 4 |
| 2026-10-02 | Cho Dennis | Sell · S | 9,514 | $188.88 | $1,797,042 | Form 4 |
| 2026-10-02 | Finn Patrick John | Sell · S | 25,714 | $188.88 | $4,856,963 | Form 4 |
| 2026-10-02 | Green Paula | Sell · S | 10,088 | $188.88 | $1,905,462 | Form 4 |
| 2026-10-02 | Laponis Adam | Sell · S | 8,057 | $188.88 | $1,521,838 | Form 4 |
| 2026-10-02 | Leproust Emily M. | Sell · S · 10b5-1 | 45,736 | $188.88 | $8,638,799 | Form 4 |
| 2026-10-02 | WERNER ROBERT F. | Sell · S | 1,482 | $188.88 | $279,926 | Form 4 |
| 2026-10-01 | Leproust Emily M. | Sell · S · 10b5-1 | 655 | $200.00 | $131,000 | Form 4 |
| 2026-09-24 | Leproust Emily M. | Sell · S · 10b5-1 | 83 | $184.60 | $15,322 | Form 4 |
| 2026-09-21 | Cho Dennis | Sell · S | 348 | $165.49 | $57,591 | Form 4 |
| 2026-09-21 | Green Paula | Sell · S | 294 | $165.49 | $48,654 | Form 4 |
| 2026-09-21 | Leproust Emily M. | Sell · S | 1,687 | $165.49 | $279,183 | Form 4 |
| 2026-09-17 | Leproust Emily M. | Sell · S · 10b5-1 | 869 | $163.39 | $141,988 | Form 4 |
| 2026-09-08 | Cho Dennis | Sell · S | 412 | $122.62 | $50,521 | Form 4 |
| 2026-09-08 | Green Paula | Sell · S | 907 | $122.62 | $111,220 | Form 4 |
| 2026-09-08 | Leproust Emily M. | Sell · S | 2,302 | $122.62 | $282,280 | Form 4 |
| 2026-09-08 | WERNER ROBERT F. | Sell · S | 238 | $122.62 | $29,185 | Form 4 |
| 2026-08-25 | Leproust Emily M. | Sell · S · 10b5-1 | 1,093 | $154.45 | $168,809 | Form 4 |
| 2026-08-24 | WERNER ROBERT F. | Sell · S | 854 | $140.77 | $120,220 | Form 4 |
| 2026-08-21 | Cho Dennis | Sell · S | 1,598 | $139.07 | $222,227 | Form 4 |
| 2026-08-21 | Finn Patrick John | Sell · S | 4,046 | $139.07 | $562,661 | Form 4 |
| 2026-08-21 | Green Paula | Sell · S | 1,360 | $139.07 | $189,130 | Form 4 |
| 2026-08-21 | Laponis Adam | Sell · S | 1,965 | $139.07 | $273,265 | Form 4 |
| 2026-08-21 | Leproust Emily M. | Sell · S | 6,639 | $139.07 | $923,259 | Form 4 |
| 2026-08-21 | WERNER ROBERT F. | Sell · S | 669 | $139.07 | $93,035 | Form 4 |
| 2026-08-19 | Cho Dennis | Sell · S · 10b5-1 | 14,205 | $129.75 | $1,843,099 | Form 4 |
| 2026-08-18 | Finn Patrick John | Sell · S · 10b5-1 | 2,000 | $122.58 | $245,162 | Form 4 |
| 2026-08-12 | BLAKE KATRYN | Sell · S | 2,240 | $122.88 | $275,251 | Form 4 |
| 2026-08-12 | Leproust Emily M. | Sell · S · 10b5-1 | 19,952 | $125.08 | $2,495,508 | Form 4 |
| 2026-08-10 | Leproust Emily M. | Sell · S · 10b5-1 | 113,318 | $125.16 | $14,183,051 | Form 4 |
| 2026-08-07 | CHESS ROBERT | Sell · S | 18,417 | $110.89 | $2,042,261 | Form 4 |
| 2026-08-05 | Cho Dennis | Sell · S · 10b5-1 | 14,205 | $109.75 | $1,558,999 | Form 4 |
| 2026-08-03 | Cho Dennis | Sell · S | 1,070 | $85.32 | $91,294 | Form 4 |
| 2026-08-03 | Finn Patrick John | Sell · S | 2,888 | $85.32 | $246,408 | Form 4 |
| 2026-08-03 | Green Paula | Sell · S | 1,133 | $85.32 | $96,669 | Form 4 |
| 2026-08-03 | Leproust Emily M. | Sell · S | 5,101 | $85.32 | $435,223 | Form 4 |
| 2026-08-03 | WERNER ROBERT F. | Sell · S | 167 | $85.32 | $14,249 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2020-03-02 | Dwight Evans | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Despite solid financial health indicators (liquidity 75, fundamentals trend 65) with narrowing losses and gross margin expansion, the near-zero catalyst score (10) driven by massive insider selling ($65M by Leproust…
The first sentence of the analysis written for TWST on 2026-10-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 3.64 · operating margin -36% — readings disagree
Suggested stop 124.04, nearest stored support minus 0.5 ATR(14.6% under the last close). Reward/risk to the next stored resistance is 0.48. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-27 Artisan Mid Cap Fund Q3 2026 Portfolio Update The portfolio generated a negative absolute return but outpaced the Russell Midcap Growth Index. During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. We ended our investment campaign in Monolithic Power Systems, FTAI Aviation and Ionis Pharmaceuticals during the quarter.
- 2026-10-23 Alger Small Cap Focus Fund Q3 2026 Portfolio Update Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and VSE Corporation were among the top detractors from performance. VSE Corporation shares detracted from performance during the quarter despite strong revenue growth, record profitability, and an improved full-year outlook.
- 2026-10-22 Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? Both of these ETFs look the part, but only one is truly the better buy for investors.
- 2026-10-18 Twist Bioscience (NASDAQ:TWST) Shares Down 7.4% – Here’s Why Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)''s stock price dropped 7.4% on Friday. The stock traded as low as $134.83 and last traded at $133.8060. 180,478 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 1,711,585 shares. The stock had previously closed at $144.49. Analyst Ratings Changes
- 2026-10-15 Polen 5Perspectives Small-Mid Growth Q3 2026 Portfolio Update During Q3 2026, the Polen 5Perspectives Small-Mid Growth Composite Portfolio returned -12.5% (net of fees) compared to the -10.4% return of the Russell 2500 Growth Index. The top contributors to the Portfolio''s relative performance in the quarter were Twist Bioscience, Twilio, and Embraer. The most significant detractors from the Portfolio''s relative performance in the quarter were nLight, Terawulf, and BWX Technologies.
- 2026-10-14 How to Invest in AI Drug Discovery .Danaher (DHR), one of the world''s largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.
- 2026-10-12 These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys? Forget the "Magnificent Seven" in favor of the "Tremendous Three"?
- 2026-10-08 Head to Head Survey: Quantum-Si (NASDAQ:QSI) versus Twist Bioscience (NASDAQ:TWST) Quantum-Si (NASDAQ: QSI - Get Free Report) and Twist Bioscience (NASDAQ: TWST - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Valuation and Earnings This table compares Quantum-Si and Twist
- 2026-10-06 Twist Bioscience (NASDAQ:TWST) Stock Falls 9.7% Following Insider Selling Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)''s share price dropped 9.7% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $186.61 and last traded at $185.0970. 1,748,314 shares traded hands during trading, an increase of 8% from the average daily volume of 1,618,778 shares.
- 2026-09-30 The Top HealthTech Questions Landing on Our Desks Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
Market snapshot
Financial ratios
| Metric | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% | |
| Ebit Margin | -20.4% | -66.5% | -83.0% | -112.1% | -116.1% | |
| Ebitda Margin | -13.8% | -56.5% | -71.1% | -104.0% | -108.7% | |
| Operating Profit Margin | -36.2% | -70.6% | -88.6% | -115.3% | -115.4% | |
| Pretax Profit Margin | -20.4% | -66.5% | -83.0% | -112.1% | -116.4% | |
| Continuous Operations Profit Margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | |
| Net Profit Margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | |
| Bottom Line Profit Margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | |
| Current Ratio | 3.643 | 4.884 | 5.786 | 6.579 | 8.667 | |
| Quick Ratio | 3.333 | 4.545 | 5.349 | 6.146 | 8.163 | |
| Solvency Ratio | -0.313 | -1.252 | -1.146 | -1.171 | -1.174 | |
| Cash Ratio | 2.003 | 3.187 | 3.907 | 4.177 | 7.388 | |
| Price To Earnings Ratio | -21.646 | -12.550 | -5.628 | -8.723 | -33.959 | |
| Price To Earnings Growth Ratio | 0.339 | 0.000 | 0.517 | -0.309 | 2.886 | |
| Forward Price To Earnings Growth Ratio | 0.339 | 0.000 | 0.517 | -0.309 | 2.886 | |
| Price To Earnings Diluted Ratio | -21.646 | -12.550 | -5.628 | -8.723 | -33.959 | |
| Price To Earnings Diluted Growth Ratio | 0.339 | 0.000 | 0.517 | -0.309 | 2.886 | |
| Price To Book Ratio | 3.558 | 5.545 | 1.849 | 2.406 | 8.886 | |
| Price To Sales Ratio | 4.469 | 8.375 | 4.702 | 9.328 | 39.003 | |
| Price To Free Cash Flow Ratio | -22.252 | -37.895 | -6.769 | -8.393 | -37.051 | |
| Price To Operating Cash Flow Ratio | -35.336 | -40.896 | -8.089 | -15.266 | -45.984 | |
| Debt To Assets Ratio | 0.214 | 0.138 | 0.121 | 0.099 | 0.090 | |
| Debt To Equity Ratio | 0.290 | 0.180 | 0.151 | 0.120 | 0.108 | |
| Debt To Capital Ratio | 0.225 | 0.152 | 0.131 | 0.107 | 0.098 | |
| Long Term Debt To Capital Ratio | 0.115 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.357 | 1.300 | 1.245 | 1.218 | 1.209 | |
| Working Capital Turnover Ratio | 1.456 | 0.999 | 0.572 | 0.412 | 0.338 | |
| Operating Cash Flow Ratio | -0.521 | -0.903 | -1.943 | -1.372 | -1.780 | |
| Operating Cash Flow Sales Ratio | -0.126 | -0.205 | -0.581 | -0.611 | -0.848 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.588 | 1.079 | 1.195 | 1.819 | 1.241 | |
| Debt Service Coverage Ratio | -3.821 | -6,112.586 | -35,060.600 | -2,515.863 | -73.987 | |
| Interest Coverage Ratio | 0.000 | -7,614.862 | -43,431.800 | -2,934.700 | -416.147 | |
| Short Term Operating Cash Flow Coverage Ratio | -3.446 | 0.000 | 0.000 | 0.000 | -72.322 | |
| Operating Cash Flow Coverage Ratio | -0.347 | -0.754 | -1.515 | -1.311 | -1.784 | |
| Capital Expenditure Coverage Ratio | -1.701 | -12.627 | -5.129 | -1.221 | -4.148 | |
| Dividend Paid And Capex Coverage Ratio | -1.701 | -12.627 | -5.129 | -1.221 | -4.148 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -31.427 | -14.034 | -5.513 | -7.630 | -33.066 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 50.7% | ▲8.1% | ▲8.6% |
| Ebit Margin | -20.4% | ▲46.1% | ▲59.2% |
| Ebitda Margin | -13.8% | ▲42.6% | ▲57.0% |
| Operating Profit Margin | -36.2% | ▲34.4% | ▲49.0% |
| Pretax Profit Margin | -20.4% | ▲46.1% | ▲59.3% |
| Continuous Operations Profit Margin | -20.6% | ▲46.1% | ▲57.9% |
| Net Profit Margin | -20.6% | ▲46.1% | ▲57.9% |
| Bottom Line Profit Margin | -20.6% | ▲46.1% | ▲57.9% |
| Current Ratio | 3.643 | ▼-1.241 | ▼-2.269 |
| Quick Ratio | 3.333 | ▼-1.212 | ▼-2.174 |
| Solvency Ratio | -0.313 | ▲0.939 | ▲0.698 |
| Cash Ratio | 2.003 | ▼-1.185 | ▼-2.130 |
| Price To Earnings Ratio | -21.646 | ▼-9.096 | ▼-5.145 |
| Price To Earnings Growth Ratio | 0.339 | ▲0.339 | ▼-0.348 |
| Forward Price To Earnings Growth Ratio | 0.339 | ▲0.339 | ▼-0.348 |
| Price To Earnings Diluted Ratio | -21.646 | ▼-9.096 | ▼-5.145 |
| Price To Earnings Diluted Growth Ratio | 0.339 | ▲0.339 | ▼-0.348 |
| Price To Book Ratio | 3.558 | ▼-1.987 | ▼-0.890 |
| Price To Sales Ratio | 4.469 | ▼-3.906 | ▼-8.706 |
| Price To Free Cash Flow Ratio | -22.252 | ▲15.642 | ▲0.220 |
| Price To Operating Cash Flow Ratio | -35.336 | ▲5.559 | ▼-6.222 |
| Debt To Assets Ratio | 0.214 | ▲0.075 | ▲0.082 |
| Debt To Equity Ratio | 0.290 | ▲0.111 | ▲0.120 |
| Debt To Capital Ratio | 0.225 | ▲0.073 | ▲0.082 |
| Long Term Debt To Capital Ratio | 0.116 | ▲0.116 | ▲0.092 |
| Financial Leverage Ratio | 1.357 | ▲0.058 | ▲0.091 |
| Working Capital Turnover Ratio | 1.456 | ▲0.457 | ▲0.701 |
| Operating Cash Flow Ratio | -0.521 | ▲0.382 | ▲0.783 |
| Operating Cash Flow Sales Ratio | -0.127 | ▲0.078 | ▲0.348 |
| Free Cash Flow Operating Cash Flow Ratio | 1.588 | ▲0.509 | ▲0.203 |
| Debt Service Coverage Ratio | -3.821 | ▲6108.765 | ▲8749.550 |
| Interest Coverage Ratio | 0.000 | ▲7614.862 | ▲10879.502 |
| Short Term Operating Cash Flow Coverage Ratio | -3.446 | ▼-3.446 | ▲11.708 |
| Operating Cash Flow Coverage Ratio | -0.347 | ▲0.407 | ▲0.795 |
| Capital Expenditure Coverage Ratio | -1.701 | ▲10.926 | ▲3.264 |
| Dividend Paid And Capex Coverage Ratio | -1.701 | ▲10.926 | ▲3.264 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -31.427 | ▼-17.393 | ▼-13.093 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.68B | $2.62B | $1.15B | $1.90B | $5.16B | |
| Enterprise value | $1.64B | $2.48B | $960.1M | $1.62B | $4.76B | |
| EV / Sales | 4.35x | 7.92x | 3.92x | 7.93x | 35.96x | |
| EV / Op. cash flow | -34.38x | -38.69x | -6.74x | -12.98x | -42.39x | |
| EV / Free cash flow | -21.65x | -35.85x | -5.64x | -7.14x | -34.16x | |
| EV / EBITDA | -31.43x | -14.03x | -5.51x | -7.63x | -33.07x | |
| Net debt / EBITDA | 0.88x | 0.80x | 1.10x | 1.34x | 2.80x | |
| Current ratio | 3.64x | 4.88x | 5.79x | 6.58x | 8.67x | |
| Income quality | 0.61x | 0.31x | 0.70x | 0.57x | 0.74x | |
| Graham net-net | $2 | $3 | $4 | $7 | $8 | |
| Tax burden | 100.9% | 100.3% | 100.6% | 95.4% | 98.7% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.2% | |
| Working capital | $241.6M | $275.8M | $350.9M | $505.8M | $483.4M | |
| Invested capital | $488.8M | $537.4M | $694.6M | $865.8M | $629.8M | |
| Return on assets | -12.1% | -34.0% | -26.4% | -22.7% | -21.7% | |
| Operating ROA | -21.7% | -31.8% | -25.0% | -28.2% | -27.7% | |
| Return on tangible assets | -14.2% | -40.6% | -32.2% | -26.7% | -23.0% | |
| Return on equity | -16.4% | -44.2% | -32.8% | -27.6% | -26.2% | |
| Return on invested capital | -24.1% | -39.6% | -30.2% | -25.3% | -23.2% | |
| Return on capital employed | -24.8% | -40.6% | -30.9% | -27.0% | -23.9% | |
| Earnings yield | -4.6% | -8.0% | -17.8% | -11.5% | -2.9% | |
| Free cash flow yield | -4.5% | -2.6% | -14.8% | -11.9% | -2.7% | |
| Capex / Op. cash flow | -58.8% | -7.9% | -19.5% | -81.9% | -24.1% | |
| Capex / Depreciation | 112.7% | 16.1% | 94.8% | 616.8% | 277.5% | |
| Capex / Sales | 7.4% | 1.6% | 11.3% | 50.0% | 20.4% | |
| SG&A / Sales | 65.6% | 69.8% | 77.4% | 104.6% | 102.7% | |
| R&D / Sales | 21.3% | 29.0% | 43.6% | 59.1% | 52.2% | |
| Stock comp / Sales | 17.1% | 16.3% | 12.4% | 39.1% | 28.0% | |
| Intangibles / Total assets | 14.9% | 16.3% | 18.1% | 15.1% | 5.8% | |
| Days sales outstanding | 56d | 41d | 66d | 72d | 79d | |
| Days payables outstanding | 22d | 3d | 33d | 61d | 67d | |
| Operating cycle | 111d | 90d | 141d | 192d | 223d | |
| Cash conversion cycle | 89d | 86d | 108d | 131d | 155d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years